This site contains promotional content intended for Healthcare Professionals in Ireland and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below.

About NUBEQA® (darolutamide) In nmCRPC

For adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease

Introducing NUBEQA:

Significantly delays metastasis with Androgen Deprivation Therapy vs. Androgen Deprivation Therapy alone, without increasing the rate of treatment discontinuation due to adverse events.

For men with nmCRPC who are at high risk of developing metastatic disease, progression to mCRPC is a tipping point for increased sufering and mortality. NUBEQA is a novel androgen receptor inhibitor for nmCRPC that extends median metastasis-free survival (MFS) without increasing the rate of treatment discontinuation due to adverse events vs. ADT alone.

The benefits of NUBEQA have been demonstrated in the ARAMIS study, the largest phase 3 study of nmCRPC to date (N=1,509).

NUBEQA® is indicated for the treatment of adult men

with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease

Do current therapies help you achieve the treatment goals of men with nmCRPC?

Delay metastasis

NUBEQA + ADT delivers:

40.4 months MFS - more than double the median MFS of ADT

FIND OUT MORE

Maintain your patient’s current lifestyle

NUBEQA + ADT delivers:

Discontinuation rate comparable
to ADT

FIND OUT MORE

Add NUBEQA to ADT to significantly delay metastasis and improve overall survival vs. ADT alone,

without increasing the rate of treatment discontinuation due to adverse events

NUBEQA® (darolutamide) | Metastasis Free Survival

Explore NUBEQA and its impact on metastasis-free survival in nmCRPC.

NUBEQA Prescribing Information

PP-NUB-IE-0265-1, December 2025

NUBEQA® (darolutamide) | Overall Survival

Explore NUBEQA and its impact on overall survival.

NUBEQA Prescribing Information

PP-NUB-IE-0266-1, December 2025

NUBEQA® (darolutamide) | Morbidity

Explore NUBEQA® and its secondary endpoints.

NUBEQA Prescribing Information

PP-NUB-IE-0267-1, December 2025

PP-NUB-IE-0264-1 | December 2025

References

1
NUBEQA® (darolutamide) Summary of Product Characteristics.
2
Fizazi K et al. N Engl J Med. 2019;380(13):1235–1246.
3
Depuy V et al. Support Care Cancer. 2007;15:869–876.
4
Gartrell BA, Saad F. Nat Rev Clin Oncol. 2014;11:335–345.
5
Kirby M et al. Int J Clin Pract. 2011;65:1180–1192.
6
McKay R et al. Prostate Cancer Prostatic Dis. 2017;20:276–282.
7
Saad F et al. Prostate Cancer Prostatic Dis. 2017;20:110–116.
8
Li TT et al. Cancer. 2017;123:3591–3601.
9
Hussain M et al. N Engl J Med. 2018;378(26):2465–2474.
10
Smith MR et al. N Engl J Med. 2018;378(15):1408–1418.
11
Anantharaman A, Small EJ. Expert Rev Anticancer Ther. 2017;17(7):625–633.
12
De Santis M, Steuber T. ESMO Open. 2019;4:e000484. doi:10.1136/esmoopen-2018-000484.
13
Drudge-Coates L et al. Clin Genitourin Cancer. 2018;16(2):e411–e419.